Carcinoembryonic antigen level of draining venous blood as a predictor of recurrence in colorectal cancer patient by Lee, Soo Young et al.
ORIGINAL ARTICLE
Copyright © 2011, the Korean Surgical Society
J Korean Surg Soc 2011;81:387-393
http://dx.doi.org/10.4174/jkss.2011.81.6.387 JKSS
Journal of the Korean Surgical Society
 pISSN 2233-7903ㆍeISSN 2093-0488
Received March 29, 2011, Revised July 8, 2011, Accepted October 6, 2011
Correspondence to: Seung Chul Heo
Department of Surgery, Seoul Metropolitan Government Seoul National University Boramae Medical Center, 20 Boramae-ro 5-gil, 
Dongjak-gu, Seoul 156-707, Korea
Tel: ＋82-2-870-2273, Fax: ＋82-2-870-3866, E-mail: heosc3@brm.co.kr
cc  Journal of the Korean Surgical Society is an Open Access Journal. All articles are distributed under the terms of the Creative Commons 
Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, 
distribution, and reproduction in any medium, provided the original work is properly cited.
Carcinoembryonic antigen level of draining venous 
blood as a predictor of recurrence in colorectal cancer 
patient
Soo Young Lee
1,2, Kyung Sun Min
3, Jung Kee Chung
1,2, In Mok Jung
2, Young Joon Ahn
2, 
Ki-Tae Hwang
2, Hye Seong Ahn
2, Seung Chul Heo
1,2
1Department of Surgery, Seoul National University College of Medicine, 
2Department of Surgery, Seoul Metropolitan Government 
Seoul National University Boramae Medical Center, 
3Department of Nuclear Medicine, Seoul National University Hospital, Seoul, 
Korea
Purpose: We designed this study to evaluate the efficacy of carcinoembryonic antigen in draining venous blood (vCEA) as a 
predictor of recurrence. Methods: Draining venous and supplying arterial bloods were collected separately during the oper-
ation of 82 colorectal cancer patients without distant metastasis from September 2004 to December 2006. Carcinoembryonic 
antigen was measured and assessed for the efficacy as a prognostic factor of recurrence using receiver operating character-
istic (ROC) and Kaplan-Meier curves. Results: vCEA is a statistically significant factor that predicts recurrence (P = 0.032) and 
the optimal cut-off value for vCEA from ROC curve is 8.0 ng/mL. The recurrence-free survival between patients with vCEA 
levels ＞8 ng/mL and ≤8 ng/mL significantly differed (P ＜  0.001). The significance of vCEA as a predictor of recurrence gets 
higher when limited to patients without lymph node metastasis. The proper cut-off value for vCEA is 4.0 ng/mL if confined 
to patients without lymph node metastasis. The recurrence-free survival between the patients of vCEA levels ＞4 ng/mL and 
≤4 ng/mL significantly differed (P ＜  0.001). Multivariate analysis revealed vCEA is an independent prognostic factor in pa-
tients without lymph node metastasis. Conclusion: vCEA is an independent prognostic factor of recurrence in colorectal can-
cer patients especially in patients without lymph node metastases.
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INTRODUCTION
Tumor node metastasis (TNM) staging system is a ma-
jor prognostic factor of colorectal cancers. However, actual 
prognosis of the patients within the same TNM stages may 
be different [1]. Therefore, various molecular markers 
have been investigated as minor prognostic factors to 
compensate for the defects of TNM staging. One of the 
most important minor prognostic factors is carcinoem-
bryonic antigen (CEA). Serum CEA have been used to de-
tect recurrence after surgery and to assess the effect of 
treatment [2-6]. CEA is a membranous protein expressed Soo Young Lee, et al.
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normally in adult and fetal intestine and usually over ex-
pressed in colorectal, breast and lung cancer [7]. CEA is a 
protein for cellular aggregation and is related to invasion 
and metastasis in colorectal cancer [8,9]. But, there are de-
bates on the efficacy of prognostic value of preoperative 
CEA levels [10-12].
CEA levels in the peripheral blood are influenced by 
many pathological and physiological factors including 
metabolism by the liver. Therefore, CEA in the draining 
venous blood (vCEA) has been known to reflect the anti-
gens expressed in the tumors better than that in the pe-
ripheral blood [13]. And there are some reports saying that 
vCEAs are more useful to predict the prognosis of color-
ectal cancers [14,15]. But more evidences are needed to de-
termine vCEA as a prognostic factor of colorectal cancer. 
Therefore, we performed this study in order to evaluate 
the possibility of vCEA as a prognostic factor of colorectal 
cancer.
METHODS
One hundred and seventy-three colorectal cancer pa-
tients were operated with curative intent at Government 
Seoul National University Boramae Medical Center from 
September 2004 to December 2006. Among them, nine-
ty-one patients were excluded due to various reasons. 
Forty-one patients who were operated on in laparoscopic 
surgery were excluded due to the technical difficulties of 
blood sampling. The decision for laparoscopic surgery 
was made as follows; Patients with tumors of T4 lesion in 
the preoperative computed tomography scan, with tu-
mors in the lower third of rectum and with intestinal adhe-
sions by previous abdominal operation were chosen to un-
dergo open surgery (these patients were included in this 
study). And because the public medical insurance of 
Korea did not cover the costs for the instruments of laparo-
scopic surgery during the study period, the laparoscopic 
surgeries were performed only in the patients who wanted 
and were willing to pay the additional costs for laparo-
scopic instruments. The other 22 of the 91 patients were ex-
cluded due to distant metastases as metastatic lesion af-
fects the CEA level of draining veins. Another 28 of the 91 
patients were excluded by failure in blood sampling due 
to small diameter of artery or vein, failure in separation of 
vein from artery, inconspicuous middle colic vessels in 
transverse colon cancer patients, and emergency 
operations. Therefore, eighty-two patients out of 173 were 
enrolled in this study.
Samplings of blood were done before the ligation of the 
feeding artery and draining vein. After dissection of the 
colon, the draining vein was clamped at its most proximal 
part and sampling was done in the congested distal vein. 
The vein was cut and ligated. Afterwards, arterial blood 
was sampled by puncture of the feeding artery, then the ar-
tery was cut and ligated. The feeding artery and draining 
vein were ileocolic artery and vein for right colon cancers, 
middle colic artery and vein for transverse colon cancer, 
and inferior mesenteric artery and vein for left colon can-
cer, sigmoid colon cancer and rectal cancers. In patients 
with colon cancer around the hepatic flexure, the vessels 
were chosen between ileocolic and middle colic vessels by 
the prominence of lymph node enlargement.
Immunoradiometric assay was used to measure CEA. 
Statistical analyses were done by receiver operating char-
acteristic (ROC) and Kaplan-Meier survival curves, Stu-
dent’s t-test and Cox regression model in the SPSS ver. 14.0 
(SPSS Inc., Chicago, IL, USA). 
RESULTS
Demographics and distribution of CEA
There were 46 male and 36 female patients and the mean 
age was 66.4 years (range, 36 to 90 years). There were 19 
right colon cancers, 3 transverse colon cancers and 60 left 
colon cancers including sigmoid and rectal cancers. Three 
patients had in situ carcinomas, nine patients had TNM 
stage I cancers, 32 patients had TNM stage II, and 38 had 
TNM stage III. Mean follow up duration was 36.6 months 
and 22 patients had distant recurrences. Local recurrence 
was not detected during the follow up period. The range of 
CEA from the feeding arteries (aCEA) were from ＜1.0 
ng/mL to 51.8 ng/mL and the range of vCEA was from 
＜1.0 ng/mL to 51.5 ng/mL. Fourteen aCEAs and ten 
vCEAs were under 1.0 ng/mL. On the assumption that Draining venous CEA as a prognostic factor
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Fig. 1. Efficacy of vCEA as a predictor of recurrence. ROC curve shows that vCEA is a statistically significant factor that predicts 
recurrence (A). There are significant differences in recurrence-free survival between high vCEA group and low vCEA group (B). 
aCEA, feeding anterial blood CEA; vCEA, draining venous blood CEA; vaCEA, difference between vCEA and aCEA (vCEA-aCEA); 
ROC, receiver operating characteristic.
Fig. 2. Recurrence-free survivals between high vCEA group and low vCEA group stratified by lymph node (LN) metastasis. There are 
significant differences in recurrence-free survival between two groups if the patient has no LN metastasis (A), but not if the patient has 
LN metastasis (B). vCEA, draining venous blood CEA.
CEA value under 1.0 ng/mL equals to 0.5 ng/mL, mean 
and standard deviation of aCEAs were 5.92 ng/mL and 
9.10 ng/mL each, and mean and standard deviation of 
vCEAs were 7.32 ng/mL and 9.98 ng/mL each. The mean of 
vCEA was higher than that of aCEA (P = 0.001).
aCEA and vCEA as prognostic factors
ROC curves of aCEA, vCEA and vaCEA (vCEA-aCEA) 
were made on the basis of specificities and sensitivities of 
recurrence (Fig. 1A). While aCEA and vaCEA were in-
eligible as prognostic factors by a significance of 0.245 and 
0.162, respectively, vCEA was identified as a significant 
prognostic factor of recurrence by the P-value of 0.032 and 
by the area under the curve of 0.656. 
The appropriate cut-off value of vCEA for optimizing 
sensitivity and specificity in predicting recurrence on the 
basis of ROC curve was 8.0 ng/mL. Recurrence rates of the 
groups with 61 patients of vCEA ≤8.0 ng/mL and with 21 
patients of vCEA ＞8.0 ng/mL were 16.4% and 57.15% 
each. The sensitivity was 54.5% and specificity was 85.0% 
for the cut-off value of 8.0 ng/mL.
Kaplan-Meier survival curve confirmed the significant 
difference in disease-free survivals between the groups of 
vCEA ≤8.0 ng/mL and of vCEA ＞8.0 ng/mL (Fig. 1B).Soo Young Lee, et al.
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Fig. 3. The efficacy of vCEA as a predictor of recurrence in patients without lymph node (LN) metastasis. ROC curve shows that vCEA 
is a more reliable prognostic factor when confined to patients without LN metastasis (A). There are significant differences in 
recurrence-free survival between high vCEA group and low vCEA group (B). vCEA, draining venous blood CEA; ROC, receiver 
operating characteristic.
Table 1. Clinicopathological factors and recurrence rate
Variable No. Recurrence rate (%) P-value
Age (yr)
   ＜65
   ≥65
31
51
25.8
27.5
0.872
Sex
   Male
   Female
46
36
30.4
22.2
0.411
Location
   A
   T
   D, S, R
19
  3
60
21.1
66.6
26.7
0.260
Tumor diameter (cm)
   ＜5
   ≥5
41
41
22.0
31.7
0.325
T category
   T0 ＋  T1 ＋  T2
   T3 ＋  T4
12
70
  8.3
30.0
0.041
N category
   Negative
   Positive
44
38
15.9
39.5
0.019
Vascular/neural invasion
   Negative
   Positive
39
43
12.8
39.5
0.005
vCEA (ng/mL)
   ≤8.0
   ＞8.0
61
21
16.4
57.1
0.002
A, ascending colon; T, transverse colon; D, S, R, descending 
colon, sigmoid colon and rectum; CEA, carcinoembryonic 
antigen.
v C E A  a s  a  p r o g n o s t i c  f a c t o r  i n  p a t i e n t s  w i t h o u t  
lymph node metastasis
If the patients were separated by the lymph node meta-
stasis, the cut-off level of vCEA (8.0 ng/mL) still made a 
statistically significant difference of disease-free survival 
in patients without lymph node metastases but did not 
make a significant difference in patients with lymph node 
metastases (Fig. 2).
If ROC curves were refined for the 44 patients without 
lymph node metastasis, the efficacy of vCEA as a prog-
nostic factor was improved by a P-value of 0.008 and area 
under the curve of 0.820 (Fig. 3A). The optimal value of 
vCEA was 4.0 ng/mL with a sensitivity of 85.7% and a spe-
cificity of 73.0%. Also Kaplan-Meier curve confirmed the 
efficacy of a new cut-off value of vCEA of 4.0 ng/mL by a 
significant difference in disease-free survivals in patients 
without lymph node metastases (P = 0.002) (Fig. 3B).
Multivariate analysis with other prognostic factors
Known prognostic factors and demographic parame-
ters as well as vCEA were evaluated for relation to prog-
nosis in all 82 patients. Age, sex, location of tumor and size 
of tumor were not related to recurrence. Meanwhile, T 
stage, N stage, neurovascular invasion and vCEA were re-
lated to tumor recurrence in univariate analysis (Table 1). 
The same parameters were also evaluated in patients with-
out lymph node metastasis (Table 2), age, sex, and location 
and size of tumors, as well as T stage and neurovascular in-
vasions not related to prognosis, while the vCEA made 
significant difference in recurrence rate between the 
groups of ＞4.0 ng/mL and ≤4 ng/mL.Draining venous CEA as a prognostic factor
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Table 2. Clinicopathological factors and recurrence rate (without 
lymph node metastasis)
No. Recurrence rate (%) P-value
Age (yr)
   ＜65
   ≥65
15
29
  6.7
20.7
0.175
Sex
   Male
   Female
26
18
19.2
11.1
0.481
Location
   A
   T
   D, S, R
10
  1
33
30.0
  0.0
12.1
0.380
Tumor diameter (cm)
   ＜5
   ≥5
21
23
14.3
17.4
0.785
T category
   T0 ＋  T1 ＋  T2
   T3 ＋  T4
12
32
  8.3
18.8
0.412
Vascular/neural invasion
   Negative
   Positive
30
14
10.0
28.6
0.192
vCEA (ng/mL)
   ≤4.0
   ＞4.0
28
16
  3.6
37.5
0.018
A, ascending colon; T, transverse colon; D, S, R, descending 
colon, sigmoid colon and rectum; CEA, carcinoembryonic 
antigen.
Table 3. Clinicopathological factors and hazard ratio (without 
lymph node metastasis)-multivariate analysis
Hazard ratio (95% CI)  P-value 
T category
   (T3 ＋  T4 vs. T0 ＋  T1 ＋  T2) 
0.278 (0.015-5.211)  0.392 
Tumor diameter (cm)
   (≥5 vs. ＜5) 
  4.387 (0.646-29.787)  0.130 
Vascular/neural invasion
   (positive vs. negative) 
  7.305 (0.924-57.783)  0.059 
vCEA (ng/mL)
   (＞4.0 vs. ≤4.0) 
 16.928 (1.735-165.116)  0.015 
CI, confidence interval.
Multivariate analysis with major clinico-pathological 
factors was done for the prognostic significance in the pa-
tients without lymph node metastasis (Table 3). T stage 
and tumor size were not related to prognosis while neuro-
vascular invasion was near significant with a P-value of 
0.059 and with a hazard ratio of 7.305. vCEA was the only 
significantly independent prognostic factor with a hazard 
ratio of 16.928.
DISCUSSION
Since the isolation of the antigen by Gold and Freedman 
[16] in 1965, CEA from peripheral vein (pCEA) has been 
widely utilized for detection of recurrence and evaluation 
of treatment. However, pCEA is influenced by various 
pathological and physiological factors such as production 
in cancer cells, secretion from cancer cells to surrounding 
tissues and lymphatics, metabolism in the liver and dilu-
tion within the blood [17,18]. Meanwhile, vCEA can be 
more useful than pCEA to predict recurrence or prognosis 
because it is less influenced by such physiological factors 
[13,14].
Some reported that preoperative pCEA would be an in-
dependent prognostic factor for recurrence after surgical 
resection in colorectal cancer patients [8,12,19-22] and oth-
ers reported that preoperative pCEA would be a prog-
nostic factor for survival [23,24]. In this study, we inves-
tigated whether the CEA from feeding artery and draining 
vein, sampled before the removal of tumor during oper-
ation, could be a prognostic factor. Mean vCEA was higher 
than that of aCEA (vCEA, 7.32; aCEA, 5.92) probably be-
cause vCEA reflects the antigens of primary tumors better 
than aCEA and because vCEA is not diluted by blood from 
other sites. 
ROC curve has been used since World War II and is a 
useful tool to evaluate the diagnostic efficacy of a signal. 
ROC curve is a graphical plot of sensitivity and 1-specific-
ity in each cut-off value of a signal and the area under the 
ROC curve (AUC) is a parameter indicating the usefulness 
of the signal in discriminating the true from the false. 
Evaluation of the vCEA, aCEA and vaCEA for the efficacy 
as a prognostic factor by ROC curve proved that aCEA, 
from the systemic circulation, is not a useful prognostic 
factor while only vCEA, from the local circulation of tu-
mor, is a significant prognostic factor of recurrence.
In previous studies, recurrences and survivals were 
evaluated in comparative groups of normal pCEA levels 
and elevated pCEA levels. But the normal reference levels 
were arbitrary in each study making it difficult to have Soo Young Lee, et al.
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consistent results and to compare results from diverse 
studies [21]. In this study, the ROC curve indicated the 
cut-off value of vCEA as 8.0 ng/mL or 4.0 ng/mL, which 
were higher or lower than the normal reference value in 
our hospital (＜5 ng/mL). These differences originated 
from the different source of blood which was either of can-
cer patients or normal population, and which was periph-
eral blood or draining venous blood.
Patients with higher vCEA levels than 8.0 ng/mL 
showed significant difference in disease-free survival 
compared to patients with lower vCEA level. This sug-
gests the possibility of more occult metastasis or more dis-
seminating conditions at or around the time of operation. 
According to Lloyd et al. [25] disseminated tumor cells ex-
isted in 32.8% of stage I and II patients and prognosis was 
poor when the disseminated tumor cells were detected in 
washings after tumor resection. All of these imply that 
there are possibilities of residual tumor cells after curative 
resection and that the current staging system alone is not 
sufficient to determine treatment level.
The value of CEA as a prognostic factor in each stage has 
long been evaluated. In some studies, preoperative high 
pCEA had a poor prognosis in only Duke’s stage C [23,26]. 
In other studies, preoperative pCEA made a difference in 
disease-free survival of stage II patients only [27]. In our 
study, vCEA was significantly related to the prognosis of 
patients without lymph node metastasis, but did not relate 
to those with lymph node metastasis. vCEA is expected to 
contribute to hematogenous metastasis because it reflects 
the antigens drained to the vein and portal circulation. 
And in patients without lymph node metastasis, the dif-
ference between patients with and without hematogenous 
metastasis is more evident, but in patients with lymph 
node metastasis the difference reduces. This correlates 
well to the results of this study that vCEA is more useful in 
patients without lymph node metastasis.
vCEA was an independent prognostic factor of re-
currence when multivariate analysis was done with major 
pathological parameters in patients without lymph node 
metastasis. The small number (44) of patients without 
lymph node metastasis made the range of 95% confidence 
interval wide and additional data from more patients are 
needed for more confident conclusions. 
The two limitations of this study are that relatively more 
patients of T4 tumors might have been included in this 
study due to excluding laparoscopic surgery and that we 
had small number of patients. Although these are not det-
rimental to this study and although we could get statistical 
significance with these patients, we need confirmation of 
the results with more patients and with new methods 
making blood sampling possible during laparoscopic 
surgery.
Adjuvant chemotherapy is recommended as standard 
treatment in stage III colorectal cancer or more but there 
are still debates on the necessity of adjuvant chemo-
therapy in stage II patients. The current recommendation 
of adjuvant chemotherapy for stage II patients by Ameri-
can Society of Clinical Oncology falls on poorly differen-
tiated cancer, T4 cancer, tumor perforation and small 
number of lymph node retrieval [28]. It is very important 
to find high-risk patients for recurrence among stage II pa-
tients and we expect the vCEA level as another candidate 
for prognostic factors in stage II patients. 
vCEA is a candidate of independent prognostic factors 
of recurrence in colorectal cancer patients without lymph 
node metastasis, although additional studies with more 
patients are necessary. 
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